image credit: Unsplash

Germany approves legislation to improve cell & gene therapy availability

June 15, 2021

The parliament advocated for an increase in the number of NUB inquiries that can take place each year. NUB inquiries are used by hospitals to gain short term reimbursement for innovative treatment and diagnostic methods, supplementing the standard Diagnosis Related Group (DRG) system. Traditionally, hospitals have only been able to make one NUB inquiry each year for Advanced Therapy Medicinal Products (ATMPs). The complexity of ATMPs means that they are usually administered in hospitals where physician services and associated care must also be reimbursed. Any extra payments then require negotiations between hospitals and insurance funds. The limit of one inquiry can make advanced therapies inaccessible to patients, even if those treatments have gained regulatory approval.

Read More on EPM Magazine